Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - March 2014

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the Month of March 2014
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2009-01473 Documents regarding the prescription drug OxyContin(Oxycodone Hydrochloride):
  • Adverse Event Reports (foreign and domestic)
  • Correspondence with Third parties.
  • Information concerning harmful interactions with other prescription drugs
  • Communications received concerning problems
  • Complaints from the public
Disclosed in part 6,336
A-2010-00586 Documents regarding the prescription drug OxyContin (Oxycodone Hydrochloride):
  • Safety and labelling issues, pre-clinical and post clinical testing
  • Safety and efficacy
  • Potential safety risks
  • Reviewers comments
(Jan 1, 1996 to Aug 11, 2010).
Disclosed in part 284
A-2011-00539 Adverse Reaction Report (AER) for Benylin. Report numbers: 000210421, 000210736, 000211643, 000213840, 000216273, 000218685, 000220106, 000224665, 000224832, 000301018, 000301053. Disclosed in part 65
A-2011-01257 All communications and documents related to a decision by Canadian Blood Services to review its policy on excluding men who have had sex with men (MSM) from donating blood. (Sep 1, 2011 to Dec 22, 2011). Disclosed in part 144
A-2011-01628 Information regarding DRIXORAL NO DRIP ORIGINAL UNSCENTED, Drug Identification Number (DIN) 02245578. Disclosed in part 63
A-2012-00464 All communications concerning the planning process, approvals menus, cost and expectations for industry-funded hospitality events at meetings of the Codex Committee on Food Labelling. (Jan. 1, 2011 to Jun 12, 2012). Disclosed in part 291
A-2012-00634 All information regarding Tysabri for Health professional in 2009. Disclosed in part 179
A-2012-00651 Documents regarding the "Pest Control Products Sales Report for 2009". (Jan 1, 2007 to Jul 31, 2012). All disclosed 49
A-2012-00734 Information regarding JAKAVI, Drug Identification Number (DIN) 02388006, 02388014, 02388022 by NOVARTIS PHARMACEUTICALS CANADA INC. Disclosed in part 23
A-2012-00828 Correspondence with the Aboriginal Affairs and Northern Development Canada concerning the eligibility of specific food and non-food products under the Food Mail Program and/or Nutrition North Canada. (Oct 1, 2009 to Aug 10, 2012). Disclosed in part 668
A-2012-00848 Documents regarding the Canada-European Union Comprehensive Economic and Trade
Agreement (CETA) negotiations that relate to proposals for changes in intellectual property protection applicable to the pharmaceutical sector, and representations made by Canadian generic pharmaceutical companies. (Sep 1 2011 to Aug 23 2012).
Disclosed in part 183
A-2012-00890 Information regarding Delsym DM, Drug Identification Number (DIN) 02018403 by Novartis Consumer Health Canada Inc. Disclosed in part 537
A-2012-01109 Documents related to a loss listed in the 2011 Public Accounts of Canada document for $63,714 for fraudulent travel claims and unreported leave of absence. Disclosed in part 4
A-2012-01275 Documents regarding Australian rules and regulations for plain package of cigarettes and other tobacco products. (Aug 1, 2012 to Dec 4, 2012) Disclosed in part 232
A-2012-01381 Documents regarding the prescription drug OxyContin (Oxycodone Hydrochloride): Memoranda, research reports, industry/stakeholder consultations and/or other documents regarding established and/or reported side effects and/or adverse effects and/or drug interactions. (Jan 1, 2009 to Jan 21, 2013). Disclosed in part 68
A-2012-01396 Information regarding Polyride-Fe Capsules, Natural Product Number (NPN) 80020979 by Seaford Pharmaceuticals Inc. Disclosed in part 132
A-2012-01614 Adverse Reaction Report (AER) for Cymbalta. Report numbers: 000374135, 000374486, 000375182, 000375224, 000376305, 000377614, 000377718, 000379839, 000379986, 000376710, 000379829. Disclosed in part 18
A-2012-01626 Adverse Reaction Report (AER) for Cymbalta. Report numbers: 000443636, 000444484, 000448894, 000449047, 000449223, 000450154, 000450534, 000452963, 000458238. Disclosed in part 15
A-2012-01630 Adverse Reaction Report (AER) for Prozac. Report numbers: 000414672, 000420801, 000422267, 000424425, 000434418. Disclosed in part 45
A-2012-01655 Adverse Reaction Report (AER) for Gliclazide. Report numbers: 000435643, 000436650, 000454824, 000437411, 000440089. Disclosed in part 19
A-2012-01658 Adverse Reaction Report (AER) for Hytrin. Report number: 000434535. Disclosed in part 6
A-2013-00003 List of studies that were submitted to the Pest Management Regulatory Agency during its initial registration of the technical grade active ingredient of Diquat for the following:
  • Dibromide (Registration No. 20218) (chemical name: 6,7 -dihydrodipyrido (1,2-a:2',1' -c) pyrazinediium)
  • Reglone Dessicant (Registration No. 26396)
Disclosed in part 5
A-2013-00014 Information regarding the document entitled: Reliance on Proprietary Data for the Purpose of Re-evaluation and Special Review (DIS2012-01) (the re-evaluation Discussion Document) and released for comment on November 30, 2012. All submissions, including those by industry participants and the general public, with respect to the Re-evaluation Discussion Document. Disclosed in part 57
A-2013-00015 Information regarding the document entitled: Reliance on Proprietary Data for the Purpose of Re-evaluation and Special Review (DIS2012-01) (the re-evaluation Discussion Document) and released for comment on November 30, 2012. All internal documents, correspondence, memoranda, summaries, notes, charts, research, in relation to the PMRA's preparation and consideration of the Re-evaluation Discussion Document. Disclosed in part 435
A-2013-00075 Adverse Reaction Report (AER) for Pantaloc. Report numbers: 000448248, 000457260, 000464543, 000476787, 000481626. Disclosed in part 12
A-2013-00080 Adverse Reaction Report (AER) for Ciclesonide. Report number: 000457038. Disclosed in part 6
A-2013-00094 All Documents including, memos, reports, studies, briefing notes that detail the approval of generic OxyContin. Disclosed in part 274
A-2013-00230 All security related policies, procedures, and technical guidelines relating to: Administrative Investigation, Security Sweeps, Physical Security, Incident reporting, the protection of Senior Executives, technical Security countermeasures, Violence in the Workplace, Communications Security, the Classification and Designation Guide and others. Disclosed in part 499
A-2013-00238 Information regarding Prevex B Cream, Drug Identification Number (DIN) 00804541. Disclosed in part 26
A-2013-00302 Information regarding Euro D 10000, Drug Identification Number (DIN) 02253178. Disclosed in part 40
A-2013-00339 Information regarding Sierrasil Joint Formula 14, Natural Product Number (NPN) 80039305. Disclosed in part 102
A-2013-00375 Adverse Reaction Report (AER) for Humira. Report numbers: 000449569, 000451817, 000453178, 000457580, 000458789, 000459326, 000459440, 000460068, 000462138. Disclosed in part 26
A-2013-00383 All reviews and reports into the Public Health Agency of Canada involvement of the 2010 Vancouver Olympics/Paralympics. Disclosed in part 105
A-2013-00533 Adverse Reaction Report (AER) for Docetaxel. Report number: 000456052. Disclosed in part 101
A-2013-00632 Copy of the deliverables submitted by Risk Sciences International (RSI) for contracts awarded to RSI. (Jan 1, 1996 to Sep 6, 2013). Disclosed in part 4,766
A-2013-00649 Any studies, interoffice memos, and/or briefing materials that discuss, analyze, or consider, in relation to Fort Chipewyan and Fort Mackay in Alberta:
  • The causal link between the oil sands development and incidences of cancer
  • Materially increases the risk of an individual developing cancer
  • Whether or not there are higher than "normal" cancer rates
(Jan 1, 2009 to Sep 18, 2013)
Disclosed in part 492
A-2013-00704 Documents pertaining to hydraulic fracturing (fracking). (Jan 1, 2013 to Sep 19, 2013). Disclosed in part 106
A-2013-00815 Letters or other correspondence with members of the Royal Canadian Mounted Police (RCMP) related to companies in the healthcare field that have operations in Canada and sell illegal and/or counterfeit products (Jan 1, 2012 to Oct 9, 2013). All exempted 0
A-2013-00826 Briefing notes:
# 13-101352-826 (Notice of Annual 2% Increase of Drug Master Files, and Certificate of Pharmaceutical Product for Publication in Canada Gazette, Part 1)
#13-107795-368 (Evaluation of the Drug Recall Process)
All disclosed 34
A-2013-00828 All briefing materials and Question Period cards on the potential impact that participation in the Trans Pacific Partnership might have on intellectual property in Canada. (Jan 1, 2012 to Oct 5, 2013). Disclosed in part 5
A-2013-00839 All communications regarding the Royal Society of Canada (RSC). (Jan 1, 2013 to Oct 22, 2013). Disclosed in part 353
A-2013-00856 Information regarding the following:
Herbal Select Standardized Ginko Biloba, numéro de produit naturel (NPN) 80006535
Allnatural, Brain Health, Ginko Biloba, NPN 80026160
Ginkgo Biloba Extract, NPN 80017970
All disclosed 7
A-2013-00903 The number of valid licences for the production of medical marihuana that are registered in the municipality of Delta, British Columbia. All disclosed 1
A-2013-00911 The number of children born and stillborn in Canada with congenital upper-limb deficiencies (LDR). (1945 to Nov 1, 2013). No records exist 0
A-2013-00912 The incidence rates per 10,000 live births and still born for children born with upper limb deficiencies. (1945 to Nov 1, 2013). No records exist 0
A-2013-00913 The number of amniocentesis procedures performed on Canadian women. (1945 to Nov 1, 2013). No records exist 0
A-2013-00914 The number of abortions performed on Canadian women. (1979 to 1999). No records exist 0
A-2013-00984 Information relative to the notice withdrawing certification of the DRX9000 TRUE NON-SURGICAL SPINAL DECOMPRESSION SYSTEM medical device in Canada, as of May 5, 2010. Disclosed in part 5
A-2013-00985 Contracts including Statement of Work for Office Relocation Services & Warehousing for the Corporate Branch, Real Property & Security Directorate. Fiscal year 2012-2013. Disclosed in part 907
A-2013-00992 Adverse Reaction Report (AER) for the following products/report numbers: Cipralex (000512406, 000514004, 000516975, 000528936, 000529351, 000529707, 000535228, 000535245, 000537589), Celexa (000519415, 000525899, 000526578, 000527837, 000529669), Treanda (000517319, 000521623) Disclosed in part 38
A-2013-00994 Copies applications to become commercial producers of medical Marihuana. (Limited to application that have passed at least the first level of review and are considered to be completely filled out). Disclosed in part 116
A-2013-01016 Adverse Reaction Report (AER) for Yaz. Report number: 000516161. Disclosed in part 3
A-2013-01031 Briefing notes for the minister about medical use of marihuana. (Jan 1, 2013 to Nov 26, 2013). Disclosed in part 33
A-2013-01033 List of financial value of Instant Awards program for Health Canada Employees. (Jan 1, 2009 to Nov 27, 2013). Disclosed in part 586
A-2013-01034 All notes considered/relied upon in preparation and during meetings with public stakeholders concerning the proposed re-evaluation decision (PRVD2012-03), Boric Acid and its Salts (Boron). (Aug 1, 2012 to Dec 31, 2012). Disclosed in part 27
A-2013-01037 Memo dated June 8, 1998 in regards to asbestos exposure with relation to employees of the Canada Revenue Agency. No records exist 0
A-2013-01042 Adverse Reaction Report (AER) for Eloxatin. Report number: 000526006. Disclosed in part 1
A-2013-01083 Actual volume value of business (Agency Nursing Service Activity Report) received by 6256253 Manitoba LTD. Dba First North Health Group under contract number H3551-112960/002/WPG and all amendments from 2012-10-31 to 2013-10-31. All disclosed 3
A-2013-01091 Audit of Mental Health Service Providers under the Non-Insured Health Benefits (NIHB) Program as per Merx Solicitation #10020112950. No records exist 0
A-2013-01109 Information regarding the drug CELEXA (including generic versions) relating to chemistry, manufacturing and design. Disclosed in part 88
A-2013-01112 FRM-019 Health Hazard Evaluation Request, 2006 - SOP-0537. Health Risk Assessment. All disclosed 25
A-2013-01114 In-depth investigations, reported incidents and adverse events pertaining to any quartz, electric, space heaters manufactured by Sunbeam or Patton or Holmes or Bionaire. (Jan 1, 1995 to (Dec 16, 2013). Disclosed in part 80
A-2013-01120 Reports and/or the advice provided to Natural Resources Canada regarding the Ripley Wind Power Project proposed by Suncor Energy Products Inc., & Acciona Wind Energy Canada Inc. (Jan 1, 2003 to Dec 31, 2007). Disclosed in part 4
A-2013-01136 The numbers of appeals for each benefit area, and the number of clients that have been approved/refused or denied in outlining the tangible benefits to First Nations. (Dec 24, 2011 to Dec 23, 2013) All disclosed 23
A-2013-01139 Documents regarding the Record of Proceedings: February 26, 2009, Scientific Advisory Committee on Oncology Therapies (SAC-OT). All disclosed 59
A-2013-01167 All interim reports, and/or memos, and/or briefing notes prepared for the Minister and/or the Minister's office on the study or the possible effects of wind turbines. Disclosed in part 180
A-2013-01178 Documents pertaining to the Special Review Initiation of 2,4-D (REV2013-06) and the regulatory status of 2,4-D in Norway considered by the department. (Sep 1, 2012 to Aug 31, 2013). Disclosed in part 44
A-2013-01186 Adverse Reaction Report (AER) for PRADAX. Report number: 000494448. Disclosed in part 4
A-2013-01187 Documents pertaining to the Special Review Initiation of 2,4-D (REV2013-06) and the regulatory status of 2,4-D in Norway considered by the department. (Sep 1, 2013 to Dec 30, 2013). Disclosed in part 6
A-2013-01191 Briefing notes for the following:
13-113706-498 - Pesticide Cost Recovery Consultation, 13-111586-62 - Update: Safe Drinking Water for First Nations Act, 13-110805-28 - Updates to the Cosmetic Ingredient Hotlist, 13-112270-977 - approval of Public Health Agency of Canada / Health Canada Public Operations Research Plan for 2013/2014 Fiscal year.
Disclosed in part 47
A-2013-01200 Document relating to the following statement:
The current practice of allowing individuals to grow marihuana for medical purposes poses risks to the safety and security of Canadians. The high value of marihuana on the illegal market increases the risks of violent home invasion and diversion to the black market.
All disclosed 91
A-2013-01239 Adverse Reaction Report (AER) for Pneumovax 23. Report number: 000472993. Disclosed in part 66
A-2013-01243 Documents relating to nursing issues or general issues at the Cape Dorset health centre in Nunavut. (Jan. 1, 2011 to Jan 20, 2014). Disclosed in part 64
A-2013-01249 All official policies, guidelines, directive or other guidance documents that govern employees (in force on January 1, 2004), when publishing, reviewing or publically presenting their scientific or technical work, belonging to the occupations classifications AG, BI, CH, DS, EN-ENG/SUR, FO, PC, RO/RCO, SE-REM/RES, SG-SRE, SP, and VM. All disclosed 46
A-2013-01256 Adverse Reaction Report (AER) for SPIRIVA. Report number: 000218228. Disclosed in part 2
A-2013-01258 Documents of companies holding a Drug Establishment Licence (DEL) in Canada (Jan 1, 2004 to Jan 23, 2014). All disclosed 27
A-2013-01271 Documents relating to outreach efforts with United States investors/entrepreneurs regarding the applications to produce medical marihuana in Canada. (Jan 1, 2013 to Jan 30, 2014). No records exist 0
A-2013-01275 Briefing note: # 13-112722-702 Memorandum to the Minister of Health: Timeline for the next steps on medical marihuana. Disclosed in part 8
A-2013-01289 The present readings of Thihalomethanes (THMs) and Haloacetic Acids (HAAs) in the water from the pump house in the Chapleau Cree Fox Lake Reserve community. (Jan 1, 2013 to Feb 3, 2014). All disclosed 1
A-2013-01294 A list of all programs and services and the financial reduction as a result of the Strategic and Operating Review. All disclosed 3
A-2013-01307 The number of full-time equivalents at the Health Canada within each of the following occupational classifications: AG, BI, CH, DS, EN-ENG/SUR, FO, PC, RO/RCO, SE-REM/RES, SG-SRE, SP and VM. (Jan 1, 2000 to Dec 31, 2013). All disclosed 2
A-2013-01308 A listing of the Access to Information requests submitted to Health Canada. (Jan 1, 2014 to Jan 31, 2014). Disclosed in part 29
A-2013-01309 Adverse Reaction Report (AER) for Adacel. Report number: 000538983. Disclosed in part 2
A-2013-01313 Adverse Reaction Report (AER) for Tubersol. Report numbers: 000542132, 000544231. Disclosed in part 3
A-2013-01318 Documents to Natural Resources Canada regarding all substation/switchyard sites for the Kingsbridge I Wind energy project, Kingsbridge 2 Wind Power Project, and the K2 wind energy power project. (Jan 1, 2002 to Jan 31, 2014). Disclosed in part 2
A-2013-01321 The number of full-time equivalents at the Public Health Agency of Canada within each of the following occupational classifications: AG, BI, CH, DS, EN-ENG/SUR, FO, PC, RO/RCO, SE-REM/RES, SG-SRE, SP and VM. (Jan 1, 2000 to Dec 31, 2013). All disclosed 1
A-2013-01323 Documents regarding advice provided to the Nova Scotia Department of Environment regarding two 1.6 megawatt turbines for the Greenfield Wind Farm in Greenfield, Nova Scotia. (Jan 1, 2006 to Dec 31, 2013). All disclosed 3
A-2013-01332 Adverse Reaction Report (AER). Report number: 000355146. Disclosed in part 2
A-2013-01333 Adverse Reaction Report (AER). Report number: 000322122. Disclosed in part 6
A-2013-01334 Adverse Reaction Report (AER). Report number: 000334112. No records exist 0
A-2013-01335 Adverse Reaction Report (AER). Report number: 000359116. Disclosed in part 2
A-2013-01336 Adverse Reaction Report (AER). Report number: 000318259. Disclosed in part 3
A-2013-01341 Adverse Reaction Report (AER). Report number: 000417418. Disclosed in part 8
A-2013-01342 Adverse Reaction Report (AER). Report number: 000330727. Disclosed in part 3
A-2013-01344 Adverse Reaction Report (AER). Report number: 000337579. Disclosed in part 1
A-2013-01346 Lists showing suppliers and including persons or consultants or firms that obtained one or more contracts and are former public servants who are receiving a pension under the Public Service Superannuation Act. (Jan 1, 2010 to Feb 7, 2014). All disclosed 4
A-2013-01351 Documents regarding Human Health Incident and Environmental Incident report 2013-4369. (Jul 23, 2013 to Feb 10, 2014). No records exist 0
A-2013-01352 Adverse Reaction Report (AER). Report number: 000436938. Disclosed in part 2
A-2013-01353 Adverse Reaction Report (AER). Report number: 000437259. Disclosed in part 3
A-2013-01357 Adverse Reaction Report (AER). Report number: 000555189. Disclosed in part 1
A-2013-01360 Adverse Reaction Report (AER) for SPIRIVA. Report number: 000301003. Disclosed in part 2
A-2013-01362 A list of every drug where a Special Access Program request was granted for the year 2013. All disclosed 10
A-2013-01364 The dates in which the greenhouse production and processing of the transgenic tomatoes were inspected and the reports of the government agencies on the inspection of the greenhouse production and processing to canned juice of the transgenic tomatoes in relation to Leamington Ontario during 2013. No records exist 0
A-2013-01368 Adverse Reaction Report (AER). Report numbers: 000548077, 000551568. Disclosed in part 4
A-2013-01369 Percentage of methamphetamine use in the town of Powerview - Pine Falls, Manitoba. No records exist 0
A-2013-01371 Adverse Reaction Report (AER) for SPIRIVA. Report number: 000315461. Disclosed in part 1
A-2013-01379 List of all requests relative to the Marihuana Medical Access Regulations (Jan 1, 2010 to Oct 31, 2012). All disclosed 3
A-2013-01384 Adverse Reaction Report (AER) for FERAHEME. Report number: 000556106. Disclosed in part 1
A-2013-01390 A copy or link to (so long as the link provides access to the complete Initiative) the Expansion and Distribution of the IMG-BC Program for Underserved Communities in British Columbia. All disclosed 24
A-2013-01391 Documents related to Expansion and Distribution of the IMG-BC (International Medical Graduates - British Columbia) Program for Underserved Communities in British Columbia. All disclosed 104
A-2013-01394 The number of individuals holding Designated-Person and Personal Use Production Licences under the Marihuana Medical Access Regulations. All disclosed 1
A-2013-01396 Documents to Natural Resources Canada regarding the Gunn's Hill Windfarm. (Jan 1, 2008 to Feb 21, 2014). No records exist 0
A-2013-01401 Adverse Reaction Report (AER) for Nasacort AQ. Report numbers: 000126622, 000127833, 000329558, 000338558, 000342720, 000347867, 000416081. Disclosed in part 8
A-2013-01414 Adverse Reaction Report (AER) for Lupron. Report number: 000541861. Disclosed in part 2
A-2013-01417 Adverse Reaction Report (AER) for Humira. Report numbers: 000553291, 00016202, 00027181. Disclosed in part 4
A-2013-01433 Memo dated June 8, 1998 on asbestos exposure at 875 Heron Road, Ottawa, Ontario. No records exist 0
A-2013-01434 Correspondence from the Canada Revenue Agency requesting pulmonary function testing and chest x-rays for different employees employed at 875 Heron Road, Ottawa, Ontario. No records exist 0
A-2013-01438 The amount of currently serving military officers who have been diagnosed with Type II diabetes. No records exist 0
A-2013-01439 Documents to Natural Resources Canada regarding the proposed Amherst Island Wind Energy Project by Windlectric Inc./Algonquin Power & Utilities Inc. (Jan 1, 2008 to Jan 31, 2014). No records exist 0
A-2013-01440 Documents to Natural Resources Canada regarding the Erie Shores Wind Farm, and Clear Creek, Cultus, and Frogmore industrial wind energy facilities. (Jan 1, 2002 to Mar 6, 2014). No records exist 0
A-2013-01459 All correspondence with the Canadian Real Estate Association (CREA) and briefing notes prepared for the Minister in relation to radon. (Jan 1, 2006 to Dec 31, 2007). No records exist 0